Article
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients.
Critical reviews in oncology/hematology - 1 Dec 2020
Malapelle Umberto, Rossi Giulio, Pisapia Pasquale, Barberis Massimo, Buttitta Fiamma, Castiglione Francesca, Cecere Fabiana Letizia, Grimaldi Antonio Maria, Iaccarino Antonino, Marchetti Antonio, Massi Daniela, Medicina Daniela, Mele Fabio, Minari Roberta, Orlando Elisabetta, Pagni Fabio, Palmieri Giuseppe, Righi Luisella, Russo Alessandro, Tommasi Stefania, Vermi William, Troncone Giancarlo
Abstract excerpt
In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.